Sign in
TerminatedEarly phase 1

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Key facts

Who runs it
University of Rochester
Where
Rochester, United StatesSee the site
Trial code
Status
Terminated
Phase
Early phase 1
People taking part
3 people enrolled
Started
17 May 2022
Ended
9 May 2024
Type of study
Interventional
Treatments tested
  • Brivaracetam
Record updated
3 June 2026
Why it stopped
lack of enrollment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18 years with pathologic diagnosis of a supratentorial diffuse astrocytic or oligodendroglial tumor
  • Patients must be able to provide informed consent

Who cannot take part

  • A pre-existing seizure disorder or epilepsy syndrome prior to tumor diagnosis
  • Active maintenance therapy with an antiepileptic seizure drug (AED) prior to diagnosis of tumor
  • Patients with active suicidal ideation or a history of suicide attempt or other serious psychiatric disorder having required hospitalization within the previous 2 years
  • Patients who have experienced an epileptic seizure as the presenting symptom of their brain tumor
  • Patients with clinically significant hepatic disease (elevated aminotransferases [bilirubin, alkaline phosphatase] > 3 times upper limit normal)
  • Patients with stage 4 or greater renal disease (GFR <30 mL/min/1.73 m2)
  • Predicted life expectancy of less than 6 months from the time of screening
  • Pregnancy
  • Patients who are unable to swallow a tablet

Where in United States

  • University of Rochester Medical CenterRochester, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.

The group in the trial

  • ExperimentalTreatment being tested

    Brivaracetam at a dose of 50 mg twice daily for 6 months

    Treatment: Brivaracetam

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 June 2026